Phio Pharmaceuticals Inc. (NASDAQ: PHIO) stock gains by 13.96% in the current market trading session. Phio Pharmaceuticals Corp. is a biotechnology business working on the next generation of immuno-oncology medicines using their INTASYSL (self-delivering RNAi) therapeutic system. The objective is to generate INTASYL therapeutic chemicals that can be used to weaponize immune effector cells and defeat tumour immune evasion.
PHIO stock’ Significant Development
Phio Pharmaceuticals released the findings of a new research showing that local treatment in vivo with INTASYL can cure tumours and develop long-lasting, tumor-specific systemic tumour immunity. These findings, which were published at the European Society of Medical Oncology (ESMO) Congress 2021, demonstrate the INTASYL technology’s promise in direct therapeutic applications.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
In a preclinical in vivo hepatocellular carcinoma model, the research was conducted to demonstrate the synergistic effect of co-targeting PD-1 and BRD4 using one INTASYL formulation (PH-3861). The findings demonstrate that when animals were given low doses of PH-3861, such as levels that were not optimal for monotherapy, up to 83 percent of them exhibited a full response. Furthermore, this treatment elicited a long-lasting and targeted anti-tumor immune response that did not require subsequent treatment.
Furthermore,
Subcutaneous Hepa1-6 tumours in mice were cured with a murine form of dual targeting INTASYL PH-3861 (mPH-3861) by local injection to the tumour at low dosages that are inappropriate for a single drug targeting either PD-1 or BRD4 alone, according to the findings reported today. Mice that were completely cured of tumours with mPH-3861 were re-challenged 2.5 months later by implanting hepatoma cancer cells in a different site than the previous tumor challenge. All of the re challenged mice that had previously been cured by mPH-3861 were cured without the need for further therapy, but tumours in the control group developed slowly as expected. These findings reveal that mPH-3861 therapy induces a long-lasting and systemic anti-tumor immune response that can stop tumour growth.
